DGAP-News
CEVEC introduces CAP(R)Go expression system for scalable production of tailor-made glycoproteins - Seite 2
"Our CAP(R)Go technology brings completely unique features to
biopharmaceuticals, placing CEVEC at the leading edge of industrial protein
manufacturing," commented Frank Ubags, Chief Executive Officer of CEVEC
Pharmaceuticals GmbH "The CAP(R)Go expression platform is designed to
manufacture normally 'difficult to produce' proteins, coagulation factors
and other plasma derived substances as wanted and needed, addressing an
increasing demand in the pharmaceutical and biotechnology industry."
About CEVEC:
Privately held CEVEC is a global solution and service provider for the
production of biopharmaceuticals based in Cologne, Germany. The Company's
core technologies, CAP(R)Go and CAP(R)GT are based on a unique human cell
expression system.
The CAP(R)Go expression platform comprises a portfolio of glyco-optimized
human suspension cell lines for tailor-made glycosylation of recombinant
proteins. The cells are highly efficient for the production of a broad
range of difficult to express glycoproteins and provide authentic human
post-translational modifications. CAP(R)Go has proven to enhance the
activity, stability and serum half-life of several candidate proteins.
The CAP(R)GT expression platform provides a fully scalable, regulatory
endorsed production system for gene therapy vectors. CAP(R)GT cells grow to
high cell densities and show a broad viral propagation spectrum including
lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV).
Furthermore, CAP(R)GT enables easier scale-up and reduced production costs
when compared to adherent cell culture systems.
Research collaborations with international pharmaceutical and biotechnology
partners followed by licensing agreements for the technology form one
revenue base for CEVEC. In addition, the Company provides contract
manufacturing for the cGMP production in CAP(R)Go and CAP(R)GT cells.
Contact:
www.cevec.com
---------------------------------------------------------------------
01.06.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
363683 01.06.2015
production of biopharmaceuticals based in Cologne, Germany. The Company's
core technologies, CAP(R)Go and CAP(R)GT are based on a unique human cell
expression system.
The CAP(R)Go expression platform comprises a portfolio of glyco-optimized
human suspension cell lines for tailor-made glycosylation of recombinant
proteins. The cells are highly efficient for the production of a broad
range of difficult to express glycoproteins and provide authentic human
post-translational modifications. CAP(R)Go has proven to enhance the
activity, stability and serum half-life of several candidate proteins.
The CAP(R)GT expression platform provides a fully scalable, regulatory
endorsed production system for gene therapy vectors. CAP(R)GT cells grow to
high cell densities and show a broad viral propagation spectrum including
lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV).
Furthermore, CAP(R)GT enables easier scale-up and reduced production costs
when compared to adherent cell culture systems.
Research collaborations with international pharmaceutical and biotechnology
partners followed by licensing agreements for the technology form one
revenue base for CEVEC. In addition, the Company provides contract
manufacturing for the cGMP production in CAP(R)Go and CAP(R)GT cells.
Contact:
CEVEC Pharmaceuticals GmbH MC Services AG
Frank Ubags Anne Hennecke
Chief Executive Officer Public Relations
T.:+49 221 46020800 T.: +49 211 52925222
E.: ubags@cevec.com E.: anne.hennecke@mc-services.eu
www.cevec.com
---------------------------------------------------------------------
01.06.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
363683 01.06.2015